Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:IMVT 11 December 2025 - 14 December 2025

Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets

Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets

Immunovant closed a $550 million stock offering on December 12, 2025, selling 26.2 million shares at $21 each. Roivant Sciences bought 16.7 million shares, investing about $350 million and increasing its stake. IMVT shares ended the week at $26.42, up 6.6% after heavy trading. The company plans to use proceeds to fund clinical trials and general operations.
14 December 2025
·
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant shares rose 9% to $25.75 Thursday after the company announced a $550 million common stock offering to fund development and possible launch of its lead drug, IMVT‑1402, for Graves’ disease. The offering priced at $21 per share, an 11% discount, and is expected to close December 12. Roivant Sciences will participate. Immunovant’s market value reached about $4 billion.
11 December 2025
····

Stock Market Today

  • Microsoft Stock Forecast: Potential to Reach $800 by 2030 Amid AI and Cloud Growth
    April 9, 2026, 8:18 AM EDT. Microsoft shares have dropped 22% year-to-date to around $369 but analysts see a 33% upside to $491 over the next year based on strong fundamentals and AI expansion. Q2 FY2026 results beat earnings estimates with revenue up 16.7% and Azure cloud growing 39%. A $625 billion commercial remaining performance obligation underpins multi-year revenue visibility. The bull case points to sustained Azure growth and OpenAI's $250 billion purchase commitment as key drivers for reaching $600+ targets. Bears caution on rising capital expenditures doubling to $29.8 billion, squeezing cash flow and AI-related losses increasing to $3.1 billion. Despite risks, the stock trades at a forward P/E of 19 with a BUY rating and 90% confidence from 24/7 Wall St. analysts, supporting a longer-term outlook potentially reaching $800 by 2030.

Latest article

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

9 April 2026
TrendForce said April 8 that Nvidia’s Rubin AI chip shipments may be delayed by HBM4 memory qualification and cooling demands, shifting over 70% of 2026 high-end GPU volume to the current Blackwell line. Rubin’s projected share dropped to 22%. Samsung began shipping HBM4 to Nvidia in February, but SK Hynix and Micron face qualification delays. Broadcom signed a long-term deal to develop Google’s TPUs through 2031.
Jim Cramer Says Wednesday’s Rally Revealed What Stocks to Buy as Micron, Memory Names Stay in Focus

Jim Cramer Says Wednesday’s Rally Revealed What Stocks to Buy as Micron, Memory Names Stay in Focus

9 April 2026
U.S. stocks rebounded sharply Wednesday, with the Dow up over 1,300 points and chipmakers jumping 6.3% as investors responded to a tentative Middle East ceasefire. Jim Cramer pointed to gains in Sherwin-Williams, Caterpillar, Home Depot, and Goldman Sachs as signals of what institutions may favor if markets stabilize. Futures slipped Thursday as oil rose on renewed ceasefire doubts and investors awaited PCE inflation data.
Go toTop